CNXU · Conexeu Sciences Inc. · Insider Trading

The reported price of $3.00 represents the purchase price per Unit. Each Unit consists of one share of Common Stock and one Warrant to purchase one share of Common Stock at an exercise price of $3.00 per share.

The reported price of $0.00 reflects that no additional consideration was paid for the Warrants beyond the $3.00 per Unit purchase price reported in Table I and described in footnote (1).

The transaction is also exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.

The Performance Warrants were granted on June 5, 2025 and have an exercise price of $0.001 and a term of 5 years. The Performance Warrants were granted for services rendered to the issuer and no price was paid for the Performance Warrants. 750,000 Performance Warrants have vested. The remaining 250,000 Performance Warrants will vest and be exercisable upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration.

The transaction is also exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.

The transaction is also exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.

The Performance Warrants were granted on June 5, 2025 and have an exercise price of $0.001 and a term of 5 years. The Performance Warrants were granted for services rendered to the issuer and no price was paid for the Performance Warrants. The Performance Warrants will vest and be exercisable upon the following milestone events: (i) 500,000 Performance Warrants upon the Issuer's listed shares of common stock trading for at least 20 consecutive trading days at a market capitalization of $80,000,000 or greater in the currency of the recognized stock exchange in North America on which the shares of common stock are listed, which have vested; and (ii) 500,000 Performance Warrants upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration.

The transaction is also exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.

The 217,608 shares of common stock acquired in Table I and the 217,608 warrants disposed of in Table II represent the exercise on September 4, 2026 of warrants held by OnePointTwo Capital Ventures LLC to purchase 217,608 shares of common stock at an exercise price of $2.30 per share.

The 2,951,848 shares of common stock reported in Table I, Column 5 are held by OnePointTwo Capital Ventures LLC and OnePointTwo Capital Ventures II LLC. OnePointTwo Capital Management LLC serves as manager of OnePointTwo Capital Ventures LLC and OnePointTwo Capital Ventures II LLC. As the managing member of OnePointTwo Capital Management LLC, Lynn Sebastian Purcell has voting and investment power over the securities held by each such entity and may therefore be deemed to beneficially own such securities. Lynn Sebastian Purcell disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any.

This Form 4 amendment is being filed solely to correct Table II, Column 5 of the Form 4 filed on September 9, 2026, which inadvertently reported the 217,608 warrants exercised on September 4, 2026 as acquired rather than disposed of. Except as expressly set forth herein, this Form 4 amendment does not amend or otherwise modify the Form 4 filed on September 9, 2026.

The 407,392 warrants reported in Table II, Column 9 are held by OnePointTwo Capital Ventures LLC. OnePointTwo Capital Management LLC serves as manager of OnePointTwo Capital Ventures LLC and OnePointTwo Capital Ventures II LLC. As the managing member of OnePointTwo Capital Management LLC, Lynn Sebastian Purcell has voting and investment power over the securities held by each such entity and may therefore be deemed to beneficially own such securities. Lynn Sebastian Purcell disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any.

900,000 Performance Warrants were granted on June 5, 2025. The Performance Warrants were granted for services rendered to the Issuer and no price was paid for the Performance Warrants. 650,000 Performance Warrants have vested. The remaining 250,000 Performance Warrants will vest and be exercisable upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration.

The reported securities are held directly by N3GU Investments LLC, a Wyoming limited liability company, over which the Reporting Person has sole voting and dispositive power.

The reported securities are held directly by N3GU Investments LLC, a Wyoming limited liability company, over which the Reporting Person has sole voting and dispositive power.

The reported securities are held directly by N3GU Investments LLC, a Wyoming limited liability company, over which the Reporting Person has sole voting and dispositive power.

900,000 Performance Warrants were granted on June 5, 2025. The Performance Warrants were granted for services rendered to the Issuer and no price was paid for the Performance Warrants. 400,000 Performance Warrants have vested. The remainder of the Performance Warrants will vest and be exercisable upon the following milestone events: (i) 250,000 Performance Warrants upon the Issuer's listed shares of common stock trading for at least 20 consecutive trading days at a market capitalization of >$80,000,000 in the currency of the recognized stock exchange in North America on which the shares of common stock are listed; and (ii) 250,000 Performance Warrants upon the Issuer's submitting a 510(k) application to the United States Food and Drug Administration.

The reported securities are held directly by N3GU Investments LLC, a Wyoming limited liability company, over which the Reporting Person has sole voting and dispositive power.

The transaction is also exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.

The Performance Warrants were granted on June 5, 2025 and have an exercise price of $0.001 and a term of 5 years. The Performance Warrants were granted for services rendered to the issuer and no price was paid for the Performance Warrants. The Performance Warrants will vest and be exercisable upon the following milestone events: (i) 500,000 Performance Warrants upon the Issuer's shares of common stock being listed on a recognized stock exchange in North America, which have vested; (ii) 500,000 Performance Warrants upon the Issuer's listed shares of common stock trading for at least 20 consecutive trading days at a market capitalization of $80,000,000 or greater in the currency of the recognized stock exchange in North America on which the shares of common stock are listed; and (iii) 500,000 Performance Warrants upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration.

The transaction is also exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.

The reported shares were issued to the Reporting Person at a deemed price of $4.00 per share for total compensation of $44,700 owing to the Reporting Person for services rendered to the issuer, which is payable in shares. No price was paid for the shares.